How have BICX shares performed in 2024?

BioCorRx's stock was trading at $0.78 at the beginning of the year. Since then, BICX stock has increased by 92.3% and is now trading at $1.50. View the best growth stocks for 2024 here .

Are investors shorting BioCorRx?

BioCorRx saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 400 shares, a decrease of 33.3% from the February 29th total of 600 shares. Based on an average trading volume of 1,400 shares, the short-interest ratio is presently 0.3 days. View BioCorRx's Short Interest .

When is BioCorRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our BICX earnings forecast .

How were BioCorRx's earnings last quarter?

BioCorRx Inc. (OTCMKTS:BICX) released its quarterly earnings data on Thursday, November, 17th. The company reported ($0.02) earnings per share (EPS) for the quarter. The firm earned $0.17 million during the quarter.

What other stocks do shareholders of BioCorRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCorRx investors own include Mondi (MNDI) , Alkermes (ALKS) , Editas Medicine (EDIT) , ImmunoGen (IMGN) , Intel (INTC) , Netflix (NFLX) , Nektar Therapeutics (NKTR) , Oracle (ORCL) , SS&C Technologies (SSNC) and AT&T (T) .

How do I buy shares of BioCorRx?

Shares of BICX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:BICX

BioCorRx (BICX) Stock Price, News & Analysis

→ top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad)

Free BICX Stock Alerts

$1.50

0.00 (0.00%)

(As of 04/15/2024 ET)

Compare

Today's Range: $1.50
▼
$1.50
50-Day Range: $0.75
▼
$1.50
52-Week Range: $0.67
▼
$2.22

Volume: 2 shs
Average Volume: 1,207 shs
Market Capitalization: $13.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Financials Headlines SEC Filings Short Interest

Get BioCorRx alerts:

Ad Traders Agency

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

About BioCorRx Stock (OTCMKTS:BICX)

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

BICX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BICX Stock News Headlines

April 9, 2024 | americanbankingnews.com

BioCorRx (OTCMKTS:BICX) Stock Crosses Above Fifty Day Moving Average of $0.90

April 3, 2024 | seekingalpha.com

BioCorRx receives new patent for novel compound to treat pain, depression, and schizophrenia

April 16, 2024 | Traders Agency (Ad)

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

April 3, 2024 | globenewswire.com

BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia

April 2, 2024 | globenewswire.com

BioCorRx Reports Business Update for 2023

February 29, 2024 | msn.com

How to Win a Business Grant: 4 Entrepreneurs Share Their Tips

February 28, 2024 | globenewswire.com

BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD

February 22, 2024 | benzinga.com

BIOCORRX INC NEW by BioCorRx Inc. Stock (OTC:BICX), Quotes and News Summary

April 16, 2024 | Traders Agency (Ad)

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

February 13, 2024 | nz.finance.yahoo.com

BioCorRx Inc. (BICX) stock price, news, quote & history – Yahoo Finance

February 8, 2024 | finance.yahoo.com

BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors

January 18, 2024 | msn.com

Collective Audience And 3 Other Stocks Under $1 Insiders Are Buying

January 9, 2024 | finance.yahoo.com

BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President

January 4, 2024 | seekingalpha.com

TAYNX Transamerica High Yield ESG-Class R4

January 3, 2024 | investing.com

Cheng Fwa Industrial Ltd (5426)

November 16, 2023 | finanznachrichten.de

BioCorRx Inc: BioCorRx Reports Business Update for the Third Quarter of 2023

November 14, 2023 | finance.yahoo.com

BioCorRx Reports Business Update for the Third Quarter of 2023

October 3, 2023 | benzinga.com

BioCorRx President Awarded $14K Worth of Stock Options

August 21, 2023 | finanznachrichten.de

BioCorRx Inc: BioCorRx Reports Business Update for the Second Quarter of 2023

August 15, 2023 | finance.yahoo.com

BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder

August 14, 2023 | finance.yahoo.com

BioCorRx Reports Business Update for the Second Quarter of 2023

July 29, 2023 | investing.com

Tokai Holdings Corp (3167)

July 29, 2023 | investing.com

Fukui Bank Ltd (8362)

July 28, 2023 | investing.com

Nissha Printing Co Ltd (7915)

July 18, 2023 | investing.com

DSC Investment Inc (241520)

July 18, 2023 | finance.yahoo.com

BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder

May 16, 2023 | finanznachrichten.de

BioCorRx Inc: BioCorRx Provides Business Update for the First Quarter of 2023

See More Headlines

Receive BICX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCorRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/17/2016
Today: 4/16/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Specialty outpatient clinics, not elsewhere classified
Sub-Industry: N/A
Current Symbol: OTCMKTS:BICX
CUSIP: N/A
CIK: 1443863
Web: www.biocorrx.com
Phone: (714) 462-4880
Fax: N/A
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-3,770,000.00
Net Margins: -4,235.96%
Pretax Margin: -4,228.35%
Return on Equity: N/A
Return on Assets: -623.19%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.03
Quick Ratio: 0.03

Sales & Book Value

Annual Sales: $90,000.00
Price / Sales: 148.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.14) per share
Price / Book: -1.32

Miscellaneous

Outstanding Shares: 8,880,000
Free Float: 6,978,000
Market Cap: $13.32 million
Optionable: Not Optionable
Beta: 0.59

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Ms. Lourdes Felix (Age 56)
CEO, CFO & Director
Comp: $250k
Mr. Louis Charles Lucido (Age 76)
President & Director
Comp: $60k
Dr. George N. Fallieras
Medical Consultant

Key Competitors

View All Competitors

BICX Stock Analysis - Frequently Asked Questions

How have BICX shares performed in 2024?: BioCorRx's stock was trading at $0.78 at the beginning of the year. Since then, BICX stock has increased by 92.3% and is now trading at $1.50.
View the best growth stocks for 2024 here.
Are investors shorting BioCorRx?: BioCorRx saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 400 shares, a decrease of 33.3% from the February 29th total of 600 shares. Based on an average trading volume of 1,400 shares, the short-interest ratio is presently 0.3 days.
View BioCorRx's Short Interest.
When is BioCorRx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our BICX earnings forecast.
How were BioCorRx's earnings last quarter?: BioCorRx Inc. (OTCMKTS:BICX) released its quarterly earnings data on Thursday, November, 17th. The company reported ($0.02) earnings per share (EPS) for the quarter. The firm earned $0.17 million during the quarter.

What other stocks do shareholders of BioCorRx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioCorRx investors own include Mondi (MNDI), Alkermes (ALKS), Editas Medicine (EDIT), ImmunoGen (IMGN), Intel (INTC), Netflix (NFLX), Nektar Therapeutics (NKTR), Oracle (ORCL), SS&C Technologies (SSNC) and AT&T (T).
How do I buy shares of BioCorRx?: Shares of BICX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:BICX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BioCorRx (BICX) Stock Price, News & Analysis

About BioCorRx Stock (OTCMKTS:BICX)

BICX Stock Price History

BICX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

BICX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info